EV Biologics (EV Biologics) FCF Yield % : 0.00 (As of May. 21, 2024)

View and export this data going back to 2015. Start your Free Trial

What is EV Biologics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, EV Biologics's Trailing 12-Month Free Cash Flow is $-5.41 Mil, and Market Cap is $5.87 Mil. Therefore, EV Biologics's FCF Yield % for today is 0.00%.

The historical rank and industry rank for EV Biologics's FCF Yield % or its related term are showing as below:

YECO's FCF Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: -14.055
* Ranked among companies with meaningful FCF Yield % only.

EV Biologics's FCF Margin % for the quarter that ended in Dec. 2017 was 0.00%.

EV Biologics FCF Yield % Historical Data

The historical data trend for EV Biologics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EV Biologics FCF Yield % Chart

EV Biologics Annual Data

Trend

Jun13

Jun14

Jun15

Jun16

Jun17

FCF Yield %

8.70

-113.53

-6.19

EV Biologics Quarterly Data
	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Jun17	Dec17
FCF Yield %	Get a 7-Day Free Trial												-572.98	1.20	-208.21	-	-

Competitive Comparison of EV Biologics's FCF Yield %

For the Biotechnology subindustry, EV Biologics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

EV Biologics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EV Biologics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where EV Biologics's FCF Yield % falls into.

EV Biologics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

EV Biologics's FCF Yield % for the fiscal year that ended in Jun. 2017 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-0.379	/	6.1241178
	=	-6.19%

EV Biologics's annualized FCF Yield % for the quarter that ended in Dec. 2017 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	0	*	4	/	6.509889
	=	0.00%

EV Biologics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

EV Biologics FCF Yield % Related Terms

Thank you for viewing the detailed overview of EV Biologics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

EV Biologics (EV Biologics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EV Biologics Inc (OTCPK:YECO) » Definitions » FCF Yield %

Comparable Companies

XCNQ:NIRV ENVB BLCM NLSP BRTX ADTX XKRX:066830 ALLR XMAD:ADL ARTL

Traded in Other Exchanges

N/A

Address

1621 Central Avenue, Cheyenne, WY, USA, 82001

Website

https://www.evbiologics.com

EV Biologics Inc is developing the extraordinary biological properties of extracellular vesicles (EVs) to create the next generation of diagnostic modalities and safe, effective biotherapeutics to improve outcomes of serious clinical conditions, increase natural longevity and transform lives.

Executives

Daniel S Mckinney	director, 10 percent owner, officer: CEO	TWO IFC, 19TH FLOOR, 8 FINANCE STREET, CENTRAL, HONG KONG F4 000000
Michael W Harlan	director	C/O WASTE CONNECTIONS, INC., 610 APPLEWOOD CRESCENT, SUITE 200, VAUGHAN A6 L4K 0C3